Serum concentration of 5-S-cysteinyldopa in pediatric patients with giant pigmented nevi

Journal of Dermatology

Volumn 23, Issue 1, 1996, Pages 16-21

  Hanawa, Yoko ^a   Wakamatsu, Kazumasa ^b   Ikeda, Shigeo ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

5 S cysteinyldopa; giant pigmented nevi; infant; skin abrasion and cryotherapy with solid carbon dioxide

Indexed keywords

BETA INTERFERON; BIOCHEMICAL MARKER; CARBON DIOXIDE; CYSTEINYLDOPA; DACARBAZINE; NIMUSTINE; TUMOR MARKER; VINCRISTINE;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONGENITAL NEVUS; CONTROLLED STUDY; CRYOTHERAPY; FEMALE; HUMAN; INFANT; MALE; MELANOGENESIS; MELANOMA; PIGMENTED NEVUS; SKIN ABRASION; SKIN TUMOR;

EID: 0030063886     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1996.tb03962.x     Document Type: Article

References (15)

1. Ito S: Melanin-related metabolites as markers of melanoma: A review, J Dermatol (Tokyo), 19: 802-805, 1992.
2. Agrup G, Falck B, Fyge K, Rorsman H, Rosengren A-M, Rosengren E: Excretion of 5-S-cysteinyldopa in the urine of healthy subjects, Acta Derm Venereal (Stockh), 55: 7-9, 1975.
3. Hansson C, Edholm L-E, Agrup G, Rorsman H, Rosengren A-M, Rosengren E: The quantitative determination of 5-S-cysteinyldopa and dopa in normal serum and in serum from patients with malignant melanoma by means of high-pressure liquid chromatography, Clin Chim Acta, 88: 419-427, 1978.
4. Agrup G, Hansson C, Juldorf F, Rorsman H, Rosengren A-M, Rosengren E: Excretion of 5-S-cysteinyldopa in humans with genetically dark skin, Acta Derm Venereol (Stockh), 59: 69-70, 1979.
5. Morishima T, Hanawa S: Urinary excretion of 5-S-cysteinyldopa in healthy Japanese, Acta Derm Venereol (Stockh), 61: 149-150, 1980.
6. Rorsman H, Agrup G, Hansson C, Rosengren E: Biochemical recorders of malignant melanoma, in McKie RM (ed): Pigment Cell, Vol 6, Karger, Basel, 1983, pp 93-115.
7. Agrup G, Agrup P, Andersson T, et al: Five years' experience of 5-S-cysteinyldopa in melanoma diagnosis, Acta Derm Venereol (Stockh), 59: 381-388, 1979.
8. Peterson LL, Woodward WR, Fletcher WS, Palmquist M, Tucker MA, Ilias A: Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects, J Am Acad Dermatol, 19: 509-515, 1988.
9. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H: Evaluation of melanin-related metabolites as markers of melanoma progression, Cancer, 73: 629-636, 1994.
10. Wakamatsu K, Ito S: Improved HPLC determination of 5-S-cysteinyldopa in serum, Clin Chem, 40: 495-496, 1994.
11. Wakamatsu K, Ito S, Horikoshi T: Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression. Melanoma Res, 1: 141-147, 1991.
12. Pers AM: Naevus pigmentosus giganticus: Indikationer for operative behandling, Ugeskr Logger, 125: 613-619, 1963.
13. Kopf AW, Bart RS, Hennessey P: Congenital nevocytic nevi and malignant melanomas, J Am Acad Dermatol, 1: 123-130, 1979.
14. Kaplan EN: The risk of malignancy in large congenital nevi, Plast Reconstr Surg, 53: 421-428, 1974.
15. Ito S, Wakamatsu K, Horikoshi T, Ishihara K: Evaluation of serum concentration of 5-S-cysteinyldopa as a biochemical marker of malignant melanoma, Skin Cancer, 10: 242-247, 1995.